<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="cmt2a" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">cmt2a</book-part-id>
      <title-group>
        <title>Charcot-Marie-Tooth Neuropathy Type 2A</title>
        <alt-title alt-title-type="alt-title">Synonyms: CMT2A, HMSN2A, HMSNIIA, Hereditary and Motor Sensory Neuropathy IIA</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="no">
          <name name-style="western">
            <surname>Z&#x000fc;chner</surname>
            <given-names>Stephan</given-names>
          </name>
          <xref ref-type="aff" rid="cmt2a.AFF1"/>
          <degrees>MD, PhD</degrees>
          <email>szuchner@med.miami.edu</email>
        </contrib>
      </contrib-group>
      <aff id="cmt2a.AFF1">Department of Human Genetics<break/>University of Miami Miller School of Medicine<break/>Miami, Florida</aff>
      <pub-history>
        <date iso-8601-date="2005-02-18" date-type="created">
          <day>18</day>
          <month>02</month>
          <year>2005</year>
        </date>
        <date iso-8601-date="2013-08-01" date-type="updated">
          <day>01</day>
          <month>08</month>
          <year>2013</year>
        </date>
        <date iso-8601-date="2010-06-10" date-type="revised">
          <day>10</day>
          <month>06</month>
          <year>2010</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="cmt2" document-type="chapter">Charcot-Marie-Tooth Neuropathy Type 2</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="cmt2e" document-type="chapter">Charcot-Marie-Tooth Neuropathy Type 2E/1F</related-object>
      <abstract id="cmt2a.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Charcot-Marie-Tooth hereditary neuropathy type 2A (CMT2A) is a classic axonal peripheral sensorimotor neuropathy characterized by earlier and more severe involvement of the lower extremities than the upper extremities, distal upper-extremity involvement as the neuropathy progresses, more prominent motor deficits than sensory deficits, and normal (&#x0003e;42 m/s) or only slightly decreased nerve conduction velocities (NCVs). Postural tremor is common. Most affected individuals develop symptoms in the first or second decade. It has recently been suggested that CMT2A represents more than 90% of the severe dominant CMT2 cases. However, milder late-onset cases and unusual presentations have also been described.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>The diagnosis is established by clinical and molecular genetic findings. <italic toggle="yes">MFN2</italic> is the only gene in which mutations are known to cause CMT2A. </p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: Treatment by a team including a neurologist, physiatrist, orthopedic surgeon, and physical and occupational therapists; special shoes and/or ankle/foot orthoses to correct foot drop and aid walking; surgery as needed for severe pes cavus; forearm crutches, canes, wheelchairs as needed for mobility; exercise as tolerated; acetaminophen or nonsteroidal anti-inflammatory agents for musculoskeletal pain; treatment of neuropathic pain with tricyclic antidepressants or drugs like carbamazepine or gabapentin.</p>
          <p><italic toggle="yes">Surveillance</italic>: Annual neurologic evaluation of gait, strength, and visual acuity.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid</italic>: Obesity (which makes ambulation more difficult); medications (e.g., vincristine, isoniazid, nitrofurantoin) known to cause nerve damage; alcohol and malnutrition (which can cause or exacerbate neuropathy).</p>
          <p><italic toggle="yes">Other</italic>: Career/employment counseling.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>CMT2A is inherited in an autosomal dominant manner. Most individuals diagnosed with CMT2A have an affected parent. The proportion of cases caused by <italic toggle="yes">de novo</italic> mutations is unknown. Each child of an individual with CMT2A has a 50% chance of inheriting the mutation. Prenatal diagnosis for pregnancies at increased risk for CMT2A is possible if the disease-causing mutation has been identified in an affected family member. </p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="cmt2a.Diagnosis">
        <title>Diagnosis</title>
        <sec id="cmt2a.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p>Charcot-Marie-Tooth hereditary neuropathy type 2A (CMT2A) is a classic axonal peripheral sensorimotor neuropathy diagnosed by molecular genetic testing of <italic toggle="yes">MFN2</italic>. </p>
          <p>No specific findings distinguish CMT2A from other types of CMT2. However, in young and severely affected individuals with CMT2, <italic toggle="yes">MFN2</italic> mutations are the most frequent cause of disease. Typical findings include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Involvement of the lower extremities earlier and more severely than the upper extremities</p>
            </list-item>
            <list-item>
              <p>Involvement of the distal upper extremities as the neuropathy progresses</p>
            </list-item>
            <list-item>
              <p>Motor deficits more prominent than sensory deficits</p>
            </list-item>
            <list-item>
              <p>Normal (&#x0003e;42 m/s) or only slightly decreased nerve conduction velocities (NCVs) [<xref ref-type="bibr" rid="cmt2a.REF.saito.1997.1630">Saito et al 1997</xref>, <xref ref-type="bibr" rid="cmt2a.REF.zuchner.2004.449">Z&#x000fc;chner et al 2004</xref>]</p>
            </list-item>
            <list-item>
              <p>Onset before age ten years (however, a wide range of age of onset has been reported)</p>
            </list-item>
          </list>
        </sec>
        <sec id="cmt2a.Molecular_Genetic_Testing">
          <title>Molecular Genetic Testing</title>
          <p><bold>Gene.</bold>
<italic toggle="yes">MFN2</italic> is the only gene in which mutations are known to cause CMT2A. </p>
          <p>
            <bold>Clinical testing</bold>
          </p>
          <table-wrap id="cmt2a.T.summary_of_molecular_genetic_tes" position="anchor" orientation="portrait">
            <label>Table 1.</label>
            <caption>
              <p>Summary of Molecular Genetic Testing Used in Charcot-Marie-Tooth Neuropathy Type 2A</p>
            </caption>
            <table>
              <tbody>
                <tr>
                  <th id="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_1" align="left" valign="middle" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_2" align="left" valign="top" rowspan="1" colspan="1">Proportion of CMT2A Attributed to Mutations in This Gene</th>
                  <th id="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Mutations Detected&#x000a0;<sup>2</sup></th>
                </tr>
                <tr>
                  <td headers="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_1" align="left" valign="middle" rowspan="3" colspan="1">
                    <italic toggle="yes">MFN2</italic>
                  </td>
                  <td headers="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_2" align="left" valign="middle" rowspan="3" colspan="1">Nearly 100%</td>
                  <td headers="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup> / mutation scanning&#x000a0;<sup>4</sup></td>
                  <td headers="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Sequence variants</td>
                </tr>
                <tr>
                  <td headers="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Sequence analysis of select exons&#x000a0;<sup>3,</sup>&#x000a0;<sup>5</sup></td>
                  <td headers="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Sequence variants in select exons</td>
                </tr>
                <tr>
                  <td headers="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_3" align="left" valign="middle" rowspan="1" colspan="1">Deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_b_cmt2a.T.summary_of_molecular_genetic_tes_1_1_1_4" align="left" valign="middle" rowspan="1" colspan="1">Exon and whole-gene deletions/duplications&#x000a0;<sup>7</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="cmt2a.TF.1">
                <label>1.</label>
                <p>See <related-object source-id="gene" document-id="cmt2a" object-id="cmt2a.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="cmt2a.TF.1.1">
                <label>2.</label>
                <p>See <xref ref-type="sec" rid="cmt2a.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants. </p>
              </fn>
              <fn id="cmt2a.TF.1.2">
                <label>3.</label>
                <p>Examples of mutations detected by sequence analysis may include small intragenic deletions/insertions and missense, nonsense, and splice site mutations; typically, exonic or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="cmt2a.TF.1.3">
                <label>4.</label>
                <p>Sequence analysis and mutation scanning of the entire gene can have similar mutation detection frequencies; however, mutation detection rates for mutation scanning may vary considerably between laboratories depending on the specific protocol used.</p>
              </fn>
              <fn id="cmt2a.TF.1.4">
                <label>5.</label>
                <p>Select exons may vary by laboratory.</p>
              </fn>
              <fn id="cmt2a.TF.1.5">
                <label>6.</label>
                <p>Testing that identifies deletions/duplications not readily detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA; included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
              </fn>
              <fn id="cmt2a.TF.1.6">
                <label>7.</label>
                <p><xref ref-type="bibr" rid="cmt2a.REF.polke.2011.168">Polke et al [2011]</xref>
</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
        <sec id="cmt2a.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband,</bold> identification of a disease-causing mutation in <italic toggle="yes">MFN2</italic> is necessary. </p>
          <list list-type="order">
            <list-item>
              <label>1</label>
              <p><italic toggle="yes">MFN2</italic> sequence analysis should be performed first. If no disease-causing mutation is found by sequence analysis, deletion/duplication analysis of <italic toggle="yes">MFN2</italic> should be considered.</p>
            </list-item>
            <list-item>
              <label>2</label>
              <p>If no disease-causing mutation in <italic toggle="yes">MFN2</italic> is identified by deletion/duplication analaysis, iterative molecular genetic testing strategies have been suggested for CMT based on extensive genetic testing results [<xref ref-type="bibr" rid="cmt2a.REF.saporta.2011.22">Saporta et al 2011</xref>].</p>
            </list-item>
          </list>
          <p><bold>Predictive testing</bold> for at-risk asymptomatic adult family members requires prior identification of the disease-causing mutation in the family.</p>
          <p><bold>Prenatal diagnosis and preimplantation genetic diagnosis (PGD)</bold> for at-risk pregnancies require prior identification of the disease-causing mutation in the family.</p>
        </sec>
      </sec>
      <sec id="cmt2a.Clinical_Description">
        <title>Clinical Characteristics</title>
        <sec id="cmt2a.Natural_History">
          <title>Clinical Description</title>
          <p>The age at onset and disease progression of Charcot-Marie-Tooth hereditary neuropathy type 2A (CMT2A) vary within and among families; onset ranges from age one year to the sixth decade. Most individuals develop symptoms in the first or second decade. The initial finding is often foot drop or foot weakness. Pes cavus foot deformity may occur.</p>
          <p>Motor signs (weakness and atrophy) predominate, but mild sensory loss in the feet is common. Tendon reflexes are usually absent, but occasionally intact.</p>
          <p>Some individuals with <italic toggle="yes">MFN2</italic> mutations are asymptomatic and have only mild findings on examination; however, those could eventually convert to late-onset cases [<xref ref-type="bibr" rid="cmt2a.REF.lawson.2005.197">Lawson et al 2005</xref>].</p>
          <p>Postural tremor is common [<xref ref-type="bibr" rid="cmt2a.REF.muglia.2001.100">Muglia et al 2001</xref>, <xref ref-type="bibr" rid="cmt2a.REF.bissartadmouri.2004.1522">Bissar-Tadmouri et al 2004</xref>].</p>
          <p>Affected individuals with early onset (age &#x0003c;10 years) tend to have more severe disability than those with later onset [<xref ref-type="bibr" rid="cmt2a.REF.chung.2006.2103">Chung et al 2006</xref>]. Those with early onset may show optic atrophy, hoarse voice, and proximal weakness. Subacute onset of optic atrophy with subsequent slow recovery in 60% of individuals with early onset was reported by <xref ref-type="bibr" rid="cmt2a.REF.zuchner.2006.276">Z&#x000fc;chner et al [2006]</xref>, and confirmed by <xref ref-type="bibr" rid="cmt2a.REF.chung.2006.2103">Chung et al [2006]</xref> and <xref ref-type="bibr" rid="cmt2a.REF.verhoeven.2006.2093">Verhoeven et al [2006]</xref>.</p>
          <p>The disease course is progressive. Although some individuals become dependent on crutches or a wheelchair, most do not [<xref ref-type="bibr" rid="cmt2a.REF.muglia.2001.100">Muglia et al 2001</xref>]. Life span is usually not reduced.</p>
          <p><bold>Neuroimaging.</bold> Periventricular and subcortical white matter lesions on brain MRI have been reported in a few individuals [<xref ref-type="bibr" rid="cmt2a.REF.chung.2006.2103">Chung et al 2006</xref>, <xref ref-type="bibr" rid="cmt2a.REF.zuchner.2006.276">Z&#x000fc;chner et al 2006</xref>].</p>
          <p><bold>Neuropathology.</bold> Neuropathologic findings include loss of myelinated nerve fibers (especially large fibers), mitochondrial abnormalities and, rarely, onion bulb formation [<xref ref-type="bibr" rid="cmt2a.REF.saito.1997.1630">Saito et al 1997</xref>, <xref ref-type="bibr" rid="cmt2a.REF.muglia.2001.100">Muglia et al 2001</xref>, <xref ref-type="bibr" rid="cmt2a.REF.verhoeven.2006.2093">Verhoeven et al 2006</xref>].</p>
        </sec>
        <sec id="cmt2a.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No apparent genotype-phenotype correlation has been reported except in one family in which truncation of the protein led to a more severe phenotype with visual impairment [<xref ref-type="bibr" rid="cmt2a.REF.zuchner.2006.276">Z&#x000fc;chner et al 2006</xref>]. Some rare families with recessive compound heterozygous changes in <italic toggle="yes">MFN2</italic> have been reported which all showed early onset of disease [<xref ref-type="bibr" rid="cmt2a.REF.polke.2011.168">Polke et al 2011</xref>]. Individuals with optic atrophy (HMSN VI) tend to show a more severe phenotype; several of these individuals were found to have a <italic toggle="yes">de novo</italic> mutation [<xref ref-type="bibr" rid="cmt2a.REF.zuchner.2006.276">Z&#x000fc;chner et al 2006</xref>]. </p>
        </sec>
        <sec id="cmt2a.Penetrance">
          <title>Penetrance</title>
          <p>The penetrance is considered to be complete. Some individuals with <italic toggle="yes">MFN2</italic> mutations are asymptomatic and have only mild findings on examination; in these cases, however, the disease may prove to be late onset [<xref ref-type="bibr" rid="cmt2a.REF.lawson.2005.197">Lawson et al 2005</xref>].</p>
        </sec>
        <sec id="cmt2a.Anticipation">
          <title>Anticipation</title>
          <p>While some authors have considered the possibility of anticipation in CMT2A, it has not been reported [<xref ref-type="bibr" rid="cmt2a.REF.muglia.2001.100">Muglia et al 2001</xref>]. </p>
        </sec>
        <sec id="cmt2a.Nomenclature">
          <title>Nomenclature</title>
          <p>CMT2A is an axonal neuropathy (indicated by the number 2) and was the first CMT2 form to be linked to a chromosomal locus (indicated by the letter A).</p>
          <p>In addition to the pure CMT2A phenotype, CMT2 with optic atrophy, also known as hereditary motor and sensory neuropathy VI (HMSN VI), has been reported in a number of individuals [<xref ref-type="bibr" rid="cmt2a.REF.zuchner.2006.276">Z&#x000fc;chner et al 2006</xref>] (see <xref ref-type="sec" rid="cmt2a.Genetically_Related_Allelic_Disord">Genetically Related Disorders</xref>). </p>
          <p><xref ref-type="bibr" rid="cmt2a.REF.chung.2006.2103">Chung et al [2006]</xref> suggested the division into "early-onset severe CMT2A phenotype" and "late-onset mild CMT2A phenotype" owing to <italic toggle="yes">MFN2</italic> mutations. All reported persons with HMSN VI with <italic toggle="yes">MFN2</italic> mutations had early-onset severe CMT2.</p>
          <p>All reported persons with HMSN VI with <italic toggle="yes">MFN2</italic> mutations had early-onset severe CMT2.</p>
        </sec>
        <sec id="cmt2a.Prevalence">
          <title>Prevalence</title>
          <p>The proportion of CMT caused by mutations in <italic toggle="yes">MFN2</italic> varies by study:</p>
          <list list-type="bullet">
            <list-item>
              <p><xref ref-type="bibr" rid="cmt2a.REF.zuchner.2004.449">Z&#x000fc;chner et al [2004]</xref> reported seven <italic toggle="yes">MFN2</italic> mutations in 36 families with CMT2, indicating that 19.5% of CMT2 could be caused by mutations in this gene.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="cmt2a.REF.chung.2006.2103">Chung et al [2006]</xref> reported that 24% of 62 families with CMT2 in South Korea had mutations in <italic toggle="yes">MFN2</italic>.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="cmt2a.REF.verhoeven.2006.2093">Verhoeven et al [2006]</xref> reported that 33% of families with CMT2 in a European/USA study had mutations in <italic toggle="yes">MFN2</italic>.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="cmt2a.REF.engelfried.2006.53">Engelfried et al [2006]</xref> reported that 8% (6/73) of persons with CMT2, including simplex cases (i.e., a single occurrence in a family), had <italic toggle="yes">MFN2</italic> mutations.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="cmt2a.REF.feely.2011.1690">Feely et al [2011]</xref> reported that CMT2A accounted for 91% of severely impaired individuals with CMT2 but only 11% of mildly or moderately impaired people.</p>
            </list-item>
            <list-item>
              <p>The majority of reported cases of optic atrophy associated with the CMT2A phenotype (previously called HMSN VI) resulted from <italic toggle="yes">de novo MFN2</italic> mutations.</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="cmt2a.Genetically_Related_Allelic_Disord">
        <title>Genetically Related (Allelic) Disorders</title>
        <p><bold><italic toggle="yes">MFN2</italic></bold>. The association of CMT2A and optic atrophy caused by mutations in <italic toggle="yes">MFN2</italic> is also known as hereditary motor and sensory neuropathy VI (HMSN VI). </p>
        <p>CMT2 with pyramidal signs, also known as HMSN VII, has been associated with <italic toggle="yes">MFN2</italic> mutations [<xref ref-type="bibr" rid="cmt2a.REF.zhu.2005.496">Zhu et al 2005</xref>]. HMSN VII is characterized by an axonal CMT phenotype with mild pyramidal signs, including extensor plantar responses, mild increase in tone, and preserved or increased reflexes, but no spastic gait [<xref ref-type="bibr" rid="cmt2a.REF.vucic.2003.696">Vucic et al 2003</xref>]. In addition, mutations in <italic toggle="yes">MFN2</italic> have been associated with early-onset stroke [<xref ref-type="bibr" rid="cmt2a.REF.chung.2008.2010">Chung et al 2008</xref>]. </p>
      </sec>
      <sec id="cmt2a.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>See <related-object link-type="booklink" source-id="gene" document-id="cmt" document-type="chapter">Charcot-Marie-Tooth Hereditary Neuropathy Overview</related-object> and <related-object link-type="booklink" source-id="gene" document-id="cmt2" document-type="chapter">Charcot-Marie-Tooth Hereditary Neuropathy Type 2</related-object>.</p>
        <p>All CMT forms in which axonal phenotypes have been reported, including <related-object link-type="booklink" source-id="gene" document-id="cmt1" document-type="chapter">CMT1A</related-object> (caused by mutations in <italic toggle="yes">PMP22</italic>), <related-object link-type="booklink" source-id="gene" document-id="cmt1" document-type="chapter">CMT1B</related-object> (caused by mutations in <italic toggle="yes">MPZ</italic>), and <related-object link-type="booklink" source-id="gene" document-id="cmtx" document-type="chapter">CMTX</related-object> (caused by mutations in <italic toggle="yes">GJB1</italic>, the gene encoding the protein connexin 32), need to be considered in the differential diagnosis of CMT2A.</p>
        <p><italic toggle="yes">MFN2</italic> mutations may prove to be the most common cause of autosomal dominant CMT2. As many as one third of all individuals with CMT2 with a positive family history have a mutation in <italic toggle="yes">MFN2</italic> [<xref ref-type="bibr" rid="cmt2a.REF.verhoeven.2006.2093">Verhoeven et al 2006</xref>]. Thus, testing of <italic toggle="yes">MFN2</italic> is probably the first genetic test to consider in families with an axonal neuropathy demonstrating male-to-male transmission.</p>
      </sec>
      <sec id="cmt2a.Management">
        <title>Management</title>
        <sec id="cmt2a.Evaluations_Following_Initial_Diag">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Charcot-Marie-Tooth hereditary neuropathy type 2A (CMT2A), the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Neurologic examination</p>
            </list-item>
            <list-item>
              <p>EMG with NCV</p>
            </list-item>
            <list-item>
              <p>Visual evoked potentials</p>
            </list-item>
            <list-item>
              <p>Medical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="cmt2a.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>The affected individual is often managed by a multidisciplinary team that includes a neurologist, physiatrist, orthopedic surgeon, and physical and occupational therapists [<xref ref-type="bibr" rid="cmt2a.REF.carter.1995.S140">Carter et al 1995</xref>]. Treatment is symptomatic and may include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Daily heel cord stretching exercises to prevent Achilles tendon shortening</p>
            </list-item>
            <list-item>
              <p>Special shoes, including those with good ankle support</p>
            </list-item>
            <list-item>
              <p>Ankle/foot orthoses to correct foot drop and aid walking [<xref ref-type="bibr" rid="cmt2a.REF.carter.1995.S140">Carter et al 1995</xref>]</p>
            </list-item>
            <list-item>
              <p>Orthopedic surgery to correct severe pes cavus deformity [<xref ref-type="bibr" rid="cmt2a.REF.holmes.1993.476">Holmes &#x00026; Hansen 1993</xref>, <xref ref-type="bibr" rid="cmt2a.REF.guyton.2000.317">Guyton &#x00026; Mann 2000</xref>]</p>
            </list-item>
            <list-item>
              <p>Forearm crutches or canes for gait stability</p>
            </list-item>
            <list-item>
              <p>Wheelchairs for mobility because of gait instability</p>
            </list-item>
            <list-item>
              <p>Exercise within the individual's capability</p>
            </list-item>
            <list-item>
              <p>Treatment of musculoskeletal pain with acetaminophen or nonsteroidal anti-inflammatory agents [<xref ref-type="bibr" rid="cmt2a.REF.carter.1998.1560">Carter et al 1998</xref>]</p>
            </list-item>
            <list-item>
              <p>Treatment of neuropathic pain with tricyclic antidepressants or drugs such as carbamazepine or gabapentin</p>
            </list-item>
            <list-item>
              <p>Career and employment counseling because of persistent weakness of hands and/or feet</p>
            </list-item>
          </list>
        </sec>
        <sec id="cmt2a.Surveillance">
          <title>Surveillance</title>
          <p>Annual neurologic evaluation of gait, strength, and visual acuity is appropriate.</p>
        </sec>
        <sec id="cmt2a.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Obesity is to be avoided because it makes walking more difficult.</p>
          <p>Medications that are toxic or potentially toxic to persons with CMT comprise a spectrum of risk ranging from definite high risk to negligible risk. Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="PDF File" xlink:href="cmt_and_medications.pdf" content-type="local-data">here</inline-supplementary-material> (pdf) for an up-to-date list.</p>
        </sec>
        <sec id="cmt2a.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="cmt2a.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="cmt2a.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p><xref ref-type="bibr" rid="cmt2a.REF.dyck.1982.239">Dyck et al [1982]</xref>, <xref ref-type="bibr" rid="cmt2a.REF.donaghy.2000.799">Donaghy et al [2000]</xref>, and <xref ref-type="bibr" rid="cmt2a.REF.ginsberg.2004.193">Ginsberg et al [2004]</xref> have described a few individuals with CMT1 and sudden deterioration in whom treatment with steroids (prednisone) or intravenous immunoglobulin has produced variable levels of improvement. No similar report on CMT2A exists.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="cmt2a.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="cmt2a.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Charcot-Marie-Tooth neuropathy type 2A (CMT2A) is inherited an autosomal dominant manner.</p>
        </sec>
        <sec id="cmt2a.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with CMT2A have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with CMT2A may have the disorder as the result of a new gene mutation. The proportion of cases caused by <italic toggle="yes">de novo</italic> mutations is unknown.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to evaluate the parents of an individual with CMT2A in order to determine which, if either, is symptomatic, both to assure appropriate medical management for that individual and for genetic counseling of the family.</p>
            </list-item>
          </list>
          <p>Note: Although most individuals diagnosed with CMT2A have an affected parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>If a parent has a disease-causing mutation, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low. No instances of germline mosaicism have been reported, although it remains a possibility.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with CMT2A has a 50% chance of inheriting the mutation.</p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the status of the proband's parents. If a parent is affected, his or her family members are at risk.</p>
        </sec>
        <sec id="cmt2a.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p><bold>Considerations in families with an apparent <italic toggle="yes">de novo</italic> mutation.</bold> When neither parent of a proband with an autosomal dominant condition has clinical evidence of the disorder or the disease-causing mutation, it is likely that the proband has a <italic toggle="yes">de novo</italic> mutation. However, possible non-medical explanations including alternate paternity or maternity (e.g., with assisted reproduction) or undisclosed adoption could also be explored.</p>
          <p><bold>Family planning</bold>
</p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy. </p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected or at risk.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals. </p>
        </sec>
        <sec id="cmt2a.Prenatal_Testing">
          <title>Prenatal Testing</title>
          <p>If the disease-causing mutation has been identified in an affected family member, prenatal testing for pregnancies at increased risk is possible by analysis of DNA extracted from fetal cells obtained by amniocentesis (usually performed at ~15-18 weeks' gestation) or chorionic villus sampling (usually performed at ~10-12 weeks' gestation).</p>
          <p>Note: Gestational age is expressed as menstrual weeks calculated either from the first day of the last normal menstrual period or by ultrasound measurements.</p>
          <p>Requests for prenatal testing for conditions which (like CMT2A) do not affect intellect or life span are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
          <p><bold>Preimplantation genetic diagnosis (PGD)</bold> may be an option for some families in which the disease-causing mutation has been identified in an affected family member. </p>
        </sec>
      </sec>
      <sec id="cmt2a.Resources">
        <title>Resources</title>
      </sec>
      <sec id="cmt2a.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="cmt2a.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The disease mechanism leading to CMT is unknown.</p>
          <sec id="cmt2a.MFN2">
            <title>
              <italic toggle="yes">MFN2</italic>
            </title>
            <p><bold>Gene structure.</bold>
<italic toggle="yes">MFN2</italic> has 17 exons and 4,546 nucleotides in the open reading frame. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="cmt2a" object-id="cmt2a.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
            <p><bold>Pathogenic allelic variants.</bold> To date, more than 50 mutations have been reported. The majority were missense muations; frameshift and nonsense mutations have also been reported [<xref ref-type="bibr" rid="cmt2a.REF.zuchner.2004.449">Z&#x000fc;chner et al 2004</xref>, <xref ref-type="bibr" rid="cmt2a.REF.verhoeven.2006.2093">Verhoeven et al 2006</xref>].</p>
            <p><bold>Normal gene product.</bold>
<italic toggle="yes">MFN2</italic> encodes a large GTPase of 757 amino acids that is situated at the outer mitochondrial membrane [<xref ref-type="bibr" rid="cmt2a.REF.rojo.2002.1663">Rojo et al 2002</xref>]. It has been shown that <italic toggle="yes">MFN2</italic> accounts for the fusion/fission balance of mitochondria [<xref ref-type="bibr" rid="cmt2a.REF.santel.2001.867">Santel &#x00026; Fuller 2001</xref>]. Recently, evidence for direct involvement of <italic toggle="yes">MFN2</italic> in fusion of mitochondria has been reported [<xref ref-type="bibr" rid="cmt2a.REF.koshiba.2004.858">Koshiba et al 2004</xref>]. The gene is ubiquitously expressed [<xref ref-type="bibr" rid="cmt2a.REF.santel.2001.867">Santel &#x00026; Fuller 2001</xref>]. </p>
            <p>Larger insertions and duplications are not known to be involved in CMT2A, but could represent rare mutational mechanisms.</p>
            <p><bold>Abnormal gene product.</bold> Most mutations are in the GTPase domain, but other parts of the protein are also affected. The GTPase domain may be crucial for the development of peripheral neuropathy. Mutations may affect both mitochondrial fusion and energy metabolism [<xref ref-type="bibr" rid="cmt2a.REF.pich.2005.1405">Pich et al 2005</xref>]. <xref ref-type="bibr" rid="cmt2a.REF.baloh.2007.422">Baloh et al [2007]</xref> reported altered axonal mitochondrial transport resulting from CMT2A-related <italic toggle="yes">MFN2</italic> mutations.</p>
          </sec>
        </sec>
      </sec>
      <sec id="cmt2a.References">
        <title>References</title>
        <sec id="cmt2a.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="cmt2a.Literature_Cited.reflist0">
            <ref id="cmt2a.REF.baloh.2007.422">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Baloh</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>RE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pestronk</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milbrandt</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth disease from mitofusin 2 mutations.</article-title>
                <source>J Neurosci.</source>
                <year>2007</year>
                <volume>27</volume>
                <fpage>422</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">17215403</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.bissartadmouri.2004.1522">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bissar-Tadmouri</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Z&#x000fc;chner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parman</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Deymeer</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serdaroglu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Gerwen</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schr&#x000f6;der</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battaloglu</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Absence of KIF1B mutation in a large Turkish CMT2A family suggests involvement of a second gene.</article-title>
                <source>Neurology.</source>
                <year>2004</year>
                <volume>62</volume>
                <fpage>1522</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15136675</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.carter.1995.S140">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carter</surname>
                    <given-names>GT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abresch</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fowler</surname>
                    <given-names>WM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kilmer</surname>
                    <given-names>DD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>CM</given-names>
                  </name>
                </person-group>
                <article-title>Profiles of neuromuscular diseases. Hereditary motor and sensory neuropathy, types I and II.</article-title>
                <source>Am J Phys Med Rehabil.</source>
                <year>1995</year>
                <volume>74</volume>
                <fpage>S140</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">7576421</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.carter.1998.1560">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Carter</surname>
                    <given-names>GT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jensen</surname>
                    <given-names>MP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Galer</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kraft</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crabtree</surname>
                    <given-names>LD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beardsley</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abresch</surname>
                    <given-names>RT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>TD</given-names>
                  </name>
                </person-group>
                <article-title>Neuropathic pain in Charcot-Marie-Tooth disease.</article-title>
                <source>Arch Phys Med Rehabil.</source>
                <year>1998</year>
                <volume>79</volume>
                <fpage>1560</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9862301</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.chung.2008.2010">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cho</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoo</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kwon</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunwoo</surname>
                    <given-names>IN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Z&#x000fc;chner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>BO</given-names>
                  </name>
                </person-group>
                <article-title>Early-onset stroke associated with a mutation in mitofusin 2.</article-title>
                <source>Neurology.</source>
                <year>2008</year>
                <volume>70</volume>
                <fpage>2010</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">18490623</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.chung.2006.2103">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chung</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eun</surname>
                    <given-names>HW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suh</surname>
                    <given-names>JS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hwang</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seo</surname>
                    <given-names>BC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Son</surname>
                    <given-names>IH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sunwoo</surname>
                    <given-names>IN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Choi</surname>
                    <given-names>BO</given-names>
                  </name>
                </person-group>
                <article-title>Early onset severe and late-onset mild Charcot-Marie-Tooth disease with mitofusin 2 (MFN2) mutations.</article-title>
                <source>Brain.</source>
                <year>2006</year>
                <volume>129</volume>
                <fpage>2103</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">16835246</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.donaghy.2000.799">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Donaghy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sisodiya</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennett</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haites</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bell</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Steroid responsive polyneuropathy in a family with a novel myelin protein zero mutation.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <year>2000</year>
                <volume>69</volume>
                <fpage>799</fpage>
                <lpage>805</lpage>
                <pub-id pub-id-type="pmid">11080236</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.dyck.1982.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dyck</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swanson</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Low</surname>
                    <given-names>PA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bartleson</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambert</surname>
                    <given-names>EH</given-names>
                  </name>
                </person-group>
                <article-title>Prednisone-responsive hereditary motor and sensory neuropathy.</article-title>
                <source>Mayo Clin Proc.</source>
                <year>1982</year>
                <volume>57</volume>
                <fpage>239</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">7070119</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.engelfried.2006.53">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Engelfried</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vorgerd</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hagedorn</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haas</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilles</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Epplen</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meins</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Charcot-Marie-Tooth neuropathy type 2A: novel mutations in the mitofusin 2 gene (MFN2).</article-title>
                <source>BMC Med Genet.</source>
                <year>2006</year>
                <volume>7</volume>
                <fpage>53</fpage>
                <pub-id pub-id-type="pmid">16762064</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.feely.2011.1690">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Feely</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laura</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siskind</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sottile</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibbons</surname>
                    <given-names>VS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reilly</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shy</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <article-title>MFN2 mutations cause severe phenotypes in most patients with CMT2A.</article-title>
                <source>Neurology.</source>
                <year>2011</year>
                <volume>76</volume>
                <fpage>1690</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21508331</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.ginsberg.2004.193">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ginsberg</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malik</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kenton</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharp</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muddle</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winer</surname>
                    <given-names>JB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Orrell</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>King</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <article-title>Coexistent hereditary and inflammatory neuropathy.</article-title>
                <source>Brain.</source>
                <year>2004</year>
                <volume>127</volume>
                <fpage>193</fpage>
                <lpage>202</lpage>
                <pub-id pub-id-type="pmid">14607795</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.guyton.2000.317">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guyton</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mann</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <article-title>The pathogenesis and surgical management of foot deformity in Charcot-Marie-Tooth disease.</article-title>
                <source>Foot Ankle Clin.</source>
                <year>2000</year>
                <volume>5</volume>
                <fpage>317</fpage>
                <lpage>26</lpage>
                <pub-id pub-id-type="pmid">11232233</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.holmes.1993.476">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Holmes</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hansen</surname>
                    <given-names>ST</given-names>
                  </name>
                </person-group>
                <article-title>Foot and ankle manifestations of Charcot-Marie-Tooth disease.</article-title>
                <source>Foot Ankle.</source>
                <year>1993</year>
                <volume>14</volume>
                <fpage>476</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">8253442</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.koshiba.2004.858">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koshiba</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Detmer</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaiser</surname>
                    <given-names>JT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCaffery</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>DC</given-names>
                  </name>
                </person-group>
                <article-title>Structural basis of mitochondrial tethering by mitofusin complexes.</article-title>
                <source>Science.</source>
                <year>2004</year>
                <volume>305</volume>
                <fpage>858</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">15297672</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.lawson.2005.197">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lawson</surname>
                    <given-names>VH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>BV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Flanigan</surname>
                    <given-names>KM</given-names>
                  </name>
                </person-group>
                <article-title>Clinical and electrophysiologic features of CMT2A with mutations in the mitofusin 2 gene.</article-title>
                <source>Neurology.</source>
                <year>2005</year>
                <volume>65</volume>
                <fpage>197</fpage>
                <lpage>204</lpage>
                <pub-id pub-id-type="pmid">16043786</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.muglia.2001.100">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Muglia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zappia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valentino</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gabriele</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Conforti</surname>
                    <given-names>FL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ragno</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazzei</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabatelli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicoletti</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patitucci</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oliveri</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bono</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gambardella</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quattrone</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Clinical and genetic study of a large Charcot-Marie-Tooth type 2A family from southern Italy.</article-title>
                <source>Neurology.</source>
                <year>2001</year>
                <volume>56</volume>
                <fpage>100</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">11148244</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.pich.2005.1405">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pich</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bach</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briones</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liesa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camps</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Testar</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palac&#x000ed;n</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zorzano</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>The Charcot-Marie-Tooth type 2A gene product, Mfn2, up-regulates fuel oxidation through expression of OXPHOS system.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2005</year>
                <volume>14</volume>
                <fpage>1405</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">15829499</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.polke.2011.168">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Polke</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laur&#x000e1;</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pareyson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taroni</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bergamin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gibbons</surname>
                    <given-names>VS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chamley</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blake</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Devile</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sandford</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sweeney</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reilly</surname>
                    <given-names>MM</given-names>
                  </name>
                </person-group>
                <article-title>Recessive axonal Charcot-Marie-Tooth disease due to compound heterozygous mitofusin 2 mutations.</article-title>
                <source>Neurology.</source>
                <year>2011</year>
                <volume>77</volume>
                <fpage>168</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">21715711</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.rojo.2002.1663">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rojo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Legros</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chateau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lomb&#x000e8;s</surname>
                    <given-names>A.</given-names>
                  </name>
                </person-group>
                <article-title>Membrane topology and mitochondrial targeting of mitofusins, ubiquitous mammalian homologs of the transmembrane GTPase Fzo.</article-title>
                <source>J Cell Sci.</source>
                <year>2002</year>
                <volume>115</volume>
                <fpage>1663</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">11950885</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.saito.1997.1630">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanaka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hozumi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>S.</given-names>
                  </name>
                </person-group>
                <article-title>Linkage mapping of the gene for Charcot-Marie-Tooth disease type 2 to chromosome 1p (CMT2A) and the clinical features of CMT2A.</article-title>
                <source>Neurology.</source>
                <year>1997</year>
                <volume>49</volume>
                <fpage>1630</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">9409358</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.santel.2001.867">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Santel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fuller</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Control of mitochondrial morphology by a human mitofusin.</article-title>
                <source>J Cell Sci.</source>
                <year>2001</year>
                <volume>114</volume>
                <fpage>867</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">11181170</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.saporta.2011.22">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saporta</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sottile</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feely</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Siskind</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shy</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <article-title>Charcot-Marie-Tooth disease subtypes and genetic testing strategies.</article-title>
                <source>Ann Neurol.</source>
                <year>2011</year>
                <volume>69</volume>
                <fpage>22</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">21280073</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.verhoeven.2006.2093">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Claeys</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Z&#x000fc;chner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schr&#x000f6;der</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceuterick</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jordanova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Vriendt</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hul</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seeman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mazanec</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saifi</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szigeti</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancias</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Butler</surname>
                    <given-names>IJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kochanski</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryniewicz</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Bleecker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van den Bergh</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verellen</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Coster</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goemans</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Auer-Grumbach</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robberecht</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milic Rasic</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nevo</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tournev</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guergueltcheva</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roelens</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vieregge</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vinci</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moreno</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christen</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shy</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lupski</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vance</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2.</article-title>
                <source>Brain.</source>
                <year>2006</year>
                <volume>129</volume>
                <fpage>2093</fpage>
                <lpage>102</lpage>
                <pub-id pub-id-type="pmid">16714318</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.vucic.2003.696">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vucic</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennerson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miedema</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kok</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholson</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>CMT with pyramidal features. Charcot-Marie-Tooth.</article-title>
                <source>Neurology.</source>
                <year>2003</year>
                <volume>60</volume>
                <fpage>696</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12601114</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.zhu.2005.496">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhu</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kennerson</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walizada</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Z&#x000fc;chner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vance</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholson</surname>
                    <given-names>GA</given-names>
                  </name>
                </person-group>
                <article-title>Charcot-Marie-Tooth with pyramidal signs is genetically heterogeneous: families with and without MFN2 mutations.</article-title>
                <source>Neurology.</source>
                <year>2005</year>
                <volume>65</volume>
                <fpage>496</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">16087932</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.zuchner.2006.276">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Z&#x000fc;chner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jordanova</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Claeys</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guergueltcheva</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cherninkova</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamilton</surname>
                    <given-names>SR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Stavern</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krajewski</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stajich</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tournev</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verhoeven</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langerhorst</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Visser</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baas</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bird</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shy</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vance</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2.</article-title>
                <source>Ann Neurol.</source>
                <year>2006</year>
                <volume>59</volume>
                <fpage>276</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">16437557</pub-id>
              </element-citation>
            </ref>
            <ref id="cmt2a.REF.zuchner.2004.449">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Z&#x000fc;chner</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mersiyanova</surname>
                    <given-names>IV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muglia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bissar-Tadmouri</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rochelle</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dadali</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zappia</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelis</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patitucci</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Senderek</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parman</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Evgrafov</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jonghe</surname>
                    <given-names>PD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsuji</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pericak-Vance</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quattrone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battaloglu</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polyakov</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timmerman</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schr&#x000f6;der</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vance</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A.</article-title>
                <source>Nat Genet.</source>
                <year>2004</year>
                <volume>36</volume>
                <fpage>449</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">15064763</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="cmt2a.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="cmt2a.Suggested_Reading.reflist0">
            <ref id="cmt2a.REF.lupski.2013.1">
              <mixed-citation publication-type="book">Lupski JR, Garcia CA. Charcot-Marie-Tooth peripheral neuropathies and related disorders. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds. <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID).</italic> 2015. New York, NY: McGraw-Hill. Chap 227.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="cmt2a.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="cmt2a.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>1 August 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>10 June 2010 (cd) Revision: edits to Agents/Circumstances to Avoid</p>
            </list-item>
            <list-item>
              <p>12 September 2007 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>23 January 2006 (cd) Revision: prenatal diagnosis for <italic toggle="yes">MFN2</italic> mutations clinically available</p>
            </list-item>
            <list-item>
              <p>18 February 2005 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>13 September 2004 (sz) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
